View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2022

ProofPilot completes $12m Series B raise to transform clinical trial model

With the funding, Wellville executive founder Esther Dyson will join the board of directors of ProofPilot.

Clinical trial software provider ProofPilot has raised over $12m in a Series B funding round led by Mitsui. The financing round saw participation from Sopris Capital, First Trust Capital Partners, and Excelra among others.

Established in 2014, ProofPilot is a Software as a Service (SaaS) clinical trial research platform.

Making trials inexpensive and simple, the company permits various companies to assess their next-generation healthcare solutions and extend to various groups of subjects.

It provides solutions to the complicated clinical trial market by providing a completely digitised platform with trial process management, self-design study and remote source verification expertise. 

ProofPilot is changing the standard trial model allowing more firms to afford to carry out trials on a broader range of regulated and non-regulated products and services, without needing traditional internal infrastructure. 

This transformation will aid small companies in designing and conducting trials rigorously and substantially boost the research capability of life science firms.

Wellville executive founder Esther Dyson will join the board of directors of ProofPilot as part of the funding. 

ProofPilot’s SaaS product allows users to create, launch, participate and engage in research studies. 

ProofPilot CEO and co-founder Matthew Amsden said: “Through our cost-effective and digitally-enabled platform, pharmaceutical and medical device companies can expand the efficacies of their existing products and explore the potential of digital health solutions. 

“For the first time, health & wellness companies can now access clinical trials to substantiate their products and services at a manageable cost. 

“Moreover, participants can seamlessly engage in clinical trial support.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU